International Conference on Gastroenterology

Intestinal rehabilitation can include nutritional, medical, or surgical techniques to enhance your quality of life. It also allows many people to enjoy a normal, oral diet without the need for intravenous or enteral (tube feeding) nutrition.

This is a medical condition characterized by excess body fat accumulation, to the extent that it may have a negative effect on health. It is typically measured using the body mass index (BMI), which is calculated by dividing weight in kilograms by height in meters squared. Obesity increases the risk of various health problems, including heart disease, diabetes, certain cancers, and musculoskeletal disorders.

The process of identifying a disease, condition, or injury based on the signs and symptoms a patient is having and the patient's health history and physical exam. Further testing, such as blood tests, imaging tests, and biopsies, may be done after a clinical diagnosis is made.

Health is the state of complete physical, mental, and social well-being and not merely the absence of disease, or infirmity. Wellness is an active process through which people become aware of, and make choices toward, a more successful existence.

A digestive disease is any health problem that occurs in the digestive tract. Conditions may range from mild to serious. Some common problems include heartburn, cancer, irritable bowel syndrome, and lactose intolerance. Other digestive diseases include: Gallstones, cholecystitis, and cholangitis.

Gallbladder stones are a very frequent condition that typically show no symptoms. Some patients have biliary colic, which is a condition where a gallstone causes temporary blockage of the cystic duct, resulting in sporadic, often intense pain in the right upper quadrant or epigastrium, and occasionally between the scapula. Cholecystitis, an acute inflammation and infection of the gallbladder, develops in the patient if the obstruction of the cystic duct continues.

Epigenetics refers to the changes in gene expression that occur without changes to the DNA sequence itself. These changes can be influenced by various factors, including environmental factors, lifestyle factors, and aging. Epigenetic changes can have significant effects on the development and progression of cancer. In cancer, epigenetic changes can lead to the activation of oncogenes, which promote cell growth and division, or the inactivation of tumor suppressor genes, which normally prevent abnormal cell growth. These changes can contribute to the development and progression of cancer. Recent research has focused on the development of epigenetic therapies for the treatment of cancer. These therapies aim to reverse the epigenetic changes that have occurred in cancer cells, leading to the reactivation of tumor suppressor genes and the inhibition of oncogene activity. Epigenetic therapies may be used alone or in combination with other treatments, such as chemotherapy or radiation therapy. Examples of epigenetic therapies currently in use or under development include DNA methylation inhibitors, histone deacetylase inhibitors, and inhibitors of enzymes involved in chromatin remodeling. These therapies have shown promising results in the treatment of various types of cancer, including leukemia, lymphoma, and solid tumors. Overall, the study of epigenetics in cancer has provided new insights into the mechanisms of cancer development and progression, and has led to the development of new therapeutic strategies for the treatment of this complex disease.

Addressing endoscopic techniques and interventional procedures, this session explores advancements in endoscopic imaging, therapeutic endoscopy, and minimally invasive treatments for gastrointestinal conditions. Discussions will cover procedural innovations, patient safety considerations, and outcomes research in endoscopic interventions. Endoscopy plays a critical role in diagnosing and treating gastrointestinal diseases, offering minimally invasive alternatives to traditional surgical approaches. By discussing endoscopic advancements and procedural techniques, this session aims to enhance procedural skills among gastroenterologists, improve patient outcomes, and promote the adoption of innovative endoscopic technologies in clinical practice.

This session focuses on IBD management, including Crohn's disease and ulcerative colitis, with discussions on personalized treatment approaches, biologic therapies, and surgical interventions. Discussions will highlight disease monitoring techniques, patient-centered care models, and psychosocial support for IBD patients. IBD is a chronic condition that significantly impacts patients' quality of life, requiring tailored management strategies to achieve remission and prevent disease complications. By sharing clinical outcomes and research advancements, this session aims to refine treatment algorithms, promote shared decision-making between patients and healthcare providers, and improve long-term outcomes for individuals living with IBD.

 Addressing therapeutic advancements, this session focuses on pharmacological treatments, minimally invasive procedures (e.g., endoscopic therapy), and surgical interventions for gastrointestinal disorders. Discussions will highlight clinical trials, outcomes research, and novel therapeutic targets in inflammatory bowel disease (IBD), gastroesophageal reflux disease (GERD), and liver diseases. Innovations in therapy aim to improve patient quality of life, reduce treatment-related complications, and achieve better disease management outcomes. By discussing therapeutic breakthroughs and best practices, this session aims to foster collaboration between clinicians, researchers, and pharmaceutical developers to accelerate the translation of research findings into clinical practice and enhance patient care.

This session explores cutting-edge diagnostic tools such as endoscopy, imaging modalities (CT, MRI), and molecular diagnostics for gastrointestinal diseases. Discussions will cover advancements in biomarker discovery, precision medicine approaches, and AI-driven diagnostic algorithms. Early and accurate diagnosis is crucial for improving patient outcomes, guiding treatment decisions, and optimizing healthcare resource utilization. By showcasing technological innovations and research advancements, this session aims to enhance diagnostic accuracy, promote interdisciplinary collaboration among gastroenterologists, radiologists, and pathologists, and pave the way for personalized medicine in gastroenterology.

Addressing gastrointestinal disorders in children, this session examines pediatric-specific conditions such as pediatric IBD, food allergies, and liver diseases. Discussions will cover diagnostic challenges, treatment approaches, and psychosocial impacts on pediatric patients and their families. Pediatric gastroenterology requires specialized care to address developmental considerations and ensure optimal growth and development. By fostering collaboration among pediatricians, gastroenterologists, and allied healthcare providers, this session aims to improve pediatric gastrointestinal health outcomes, advance pediatric gastroenterology research, and enhance care delivery for young patients worldwide.

This session focuses on nutritional management strategies, dietary interventions, and lifestyle modifications for gastrointestinal conditions such as celiac disease, irritable bowel syndrome (IBS), and obesity-related liver disease. Discussions will highlight evidence-based dietary guidelines, nutritional support in chronic illnesses, and the role of diet in gut health maintenance. Nutrition plays a pivotal role in preventing and managing gastrointestinal disorders, influencing disease progression and treatment outcomes. By addressing nutritional challenges and promoting dietary education, this session aims to empower healthcare professionals, dietitians, and patients with practical strategies to optimize gastrointestinal health and improve overall well-being.

This session explores the pathophysiology, diagnosis, and management of FGIDs, including disorders like functional dyspepsia, irritable bowel syndrome (IBS), and functional constipation. Discussions will cover symptom-based management strategies, dietary interventions, and the role of psychological factors in FGID etiology. FGIDs are common and can significantly impact patients' quality of life, necessitating comprehensive approaches that address both physical and psychosocial aspects. By sharing clinical insights and research advancements, this session aims to refine diagnostic criteria, optimize treatment algorithms, and enhance patient-centered care for individuals suffering from FGIDs globally.

Addressing the gut microbiome's role in health and disease, this session explores microbiota composition, microbial metabolites, and their impact on gastrointestinal disorders. Discussions will cover microbiome-host interactions, probiotic/prebiotic therapies, and microbiome-modulating interventions. The gut microbiome influences digestive function, immune response, and metabolic processes, highlighting its relevance to gastroenterology research. By examining microbiome-related research findings and clinical applications, this session aims to advance understanding of microbial contributions to disease pathogenesis, guide microbiome-targeted therapies, and promote personalized medicine approaches in gastroenterology.

This session examines the latest research on gastrointestinal cancers, including colorectal cancer, pancreatic cancer, and liver cancer. Discussions will cover molecular pathways, immunotherapy approaches, and targeted therapies for cancer treatment. Gastrointestinal cancers pose significant health challenges globally, requiring multidisciplinary approaches involving oncologists, surgeons, and researchers. By sharing insights into cancer biology, treatment strategies, and survivorship care, this session aims to advance knowledge in oncology, improve early detection rates, and optimize cancer treatment outcomes through personalized and evidence-based approaches.

Addressing liver diseases, including viral hepatitis, non-alcoholic fatty liver disease (NAFLD), and liver cirrhosis, this session examines epidemiology, risk factors, and therapeutic strategies. Discussions will cover liver transplantation advancements, disease progression models, and interventions to mitigate liver damage. Liver diseases represent a significant global health burden, requiring integrated approaches involving hepatologists, transplant surgeons, and researchers. By discussing liver disease prevention, early detection, and management strategies, this session aims to improve liver health outcomes, reduce disease prevalence, and enhance healthcare systems' capacity to address liver-related challenges effectively.